• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH

ALTERITY THERAPEUTICS LIMITED

0.00% ! 1.3¢
Market Cap $119.6M  !

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ATH
Stock price - ATH/ATHE
40 41 42
20/08/25 2.4K 813K
20/08/25 Last post  itsagas Comments Created with Sketch.  2.4K  Views Created with Sketch.  813K 
ATH
News, articles and interviews
3 4 5
20/08/25 279 102K
20/08/25 Last post  Fluidmotion Comments Created with Sketch.  279  Views Created with Sketch.  102K 
ATH
Massive cap , dangerous times .
20/08/25 2 437
Metals & Mining SECTOR NEWS

Redcastle Resources (ASX:RC1): Strategic JV to Expedite Gold Production & Major Tenement Expansion in Eastern Goldfields

RC1
20 Aug 2025
REDCASTLE RESOURCES LIMITED
20/08/25 Last post  itsagas Comments Created with Sketch.  2  Views Created with Sketch.  437 
ATH
Ferroptosis in women's health and diseases
19/08/25 0 154
19/08/25 Last post  pivalde Comments Created with Sketch.  0  Views Created with Sketch.  154 
ATH
Iron pathology in Epilepsy
19/08/25 3 1.2K
19/08/25 Last post  pivalde Comments Created with Sketch.  3  Views Created with Sketch.  1.2K 
ATH
AA approval - confusion
19/08/25 10 2.3K
19/08/25 Last post  GazBusey Comments Created with Sketch.  10  Views Created with Sketch.  2.3K 
ATH
A new ATH434 paper by Kosman et al
18/08/25 1 438
18/08/25 Last post  pivalde Comments Created with Sketch.  1  Views Created with Sketch.  438 
ATH
Buy-out or partnership ???
16/08/25 2 889
16/08/25 Last post  Scottsmyname Comments Created with Sketch.  2  Views Created with Sketch.  889 

See All Discussions arrow Created with Sketch.

Timeline

Notification regarding unquoted securities - ATH
15 Aug 14:53
 
Notification regarding unquoted securities - ATH
15 Aug 14:51
 
Response to ASX Query Letters
04 Aug 12:42
 
Updated Corporate Presentation
31 Jul 08:47
 
Quarterly Activities/Appendix 4C Cash Flow Report
30 Jul 10:13
 
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
28 Jul 09:59
 
View More arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.3¢
Change
0.000(0.00%)
Mkt cap ! $119.6M
Open High Low Value Volume
1.3¢ 1.4¢ 1.3¢ $6.295K 481.2K

Buyers (Bids)

No. Vol. Price($)
58 23631783 1.3¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 14268786 13
View Market Depth
Last trade - 16.10pm 20/08/2025 (20 minute delay) ?
Last
1.4¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
1.4¢ 1.4¢ 1.3¢ 4032400
Last updated 14.38pm 20/08/2025 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.